Home

医療・福祉機器産業支援調査事業

image

Contents

1.
2.
3.
4.
5.
6. 3
7. 6
8. 10 Produced by CSS
9. 1 2 9 3 gt
10. 3 23 2 WINC AICHI
11. 22 1 22 12 9 14 00 16 45 92 122
12. BAN Produced by CSS 2 4 Pg 2010 12 20 yu o
13. 3
14. O 15 00 15 05
15. NSR 2 gt
16. O3 3501 1562 aa a I 2529 enoes
17. a RG 3 td 1 8 MI gt rm 1S013485 QMS Si
18. 6 r 9
19. 16 1 a 0 OL EN 0 2
20. 2006 3 ed gt GQP GVP gt retire PL X 1
21. e 12 gt H22 11 1 H22 11 9 H22 11 25 H22 11 30 H22 12 1 H22 12 20 H22 12 11 H22 12 21 9 22
22. 1 2 3 SO 1 2040 12 20 DENSO DENSO CORPORATION All right Teiomalonis he exclusive property of DENSO CORPORATION Whoct her consent may not be reproduced ar gven i DENSO DENSO CORPORATION Allrights reserved 1 1 Le we gt 1 ji 1 tH i 6 0 L ji Me
23. 6
24. 2 5 22 1
25. Tul 66 1 16 33 25 1 1 NALIC
26. 2 Produced by CSS 2011 2 24 MT ll REC A A gt gt gt
27. 8 0 4
28. CLINCAL STUDY SUPPORT O52 784 6G321 22 1 22 11 5 14 00 16 30 19 19 13 30 14 00 14 10 15 00 15 00 16 10 16 15 16 30 16 40 CLINICAL STUDY SUPPORT
29. Produced by CSS 22 11 12 co 1 2 3 4 5 6 7 8 9 1
30. 2 1 50 O 4 5 2 1 1 3 1
31. NPO 1 BAN BAN 6
32. 4 20 22 4
33. 1 12 4 1 3 gt
34. a a _ i 8 SS HE 2010 12 09 9
35. 1 3 18 10 1 1
36. 5 21 22
37. 6 I ASTMF136 Produced by CSS 3 23 2 1
38. 9896 70 2 2 59779 5 22
39. RA Produced by CSS 14 1 4000 3000 2000 1000 6 2 Bone and Joint Decade 0 10 2000 2010 a lt
40. 11 22 71 8 4 7 8 6 66 4 59 1 1 3 3 4 1 2 2
41. i wa NN lS Ot 2 US 22 Ni 7 2011 2 6 Ri 7 1 1 K600 IABP 1
42. lt o
43. 4 2 1 15 1 2 1 22 11 5 14 00 lt 16 30
44. Produced by CSS 1 22 2 12 9 14 00 16 45 1 000 120
45. 17 10 17 30 17 45 JA NPO 3 2 65 6 SN JR JR IB 3
46. E CLINICAL STUDY SUPPORT CSS e mail 2 2 8 22
47. o 76 1 3 o o o 2 TIOZ o o o 1
48. na IRB iT CRC SMO CRC CRP Global CRO Early phase Systems Biology Drug Repositioning SAGE Bionetworks NPO Harvard Global Cures Harvard Lab for Personalized Medicine HBD Harmonisation by Doing Duke POc PMDA FDA 15 GCP 2
49. 39 6 4 409 6 50 EU3096 35 10 2000 m EU R amp D R amp D 1096 13 R amp D 69 R amp D 696 M amp A EU M amp A ek 4 297 938 2005 98 148 2005
50. QMS 0306001 Ca X 008001 JIS T0993 1 2 I QMS JIS T2008
51. 2 3 2 i 1 2 3 1
52. 15 1 0 7 8 Produced by CSS 22 100 0 80 0 60 0 40 0 20 0 0 0 2 77 9 7 7 0 2 1 SOS 100 0 80 0 60 0 0 40 0 26 9 26 9 20 0 0 0 3
53. 22 8 1 3 694 870 531 2 6 956 301 450 161 1 1 871 5 810 230 618 5 9 394 2 400 220 1 729 2 1 388 1 260 180 192 9 6 533 53 350 18 4 2 899 1 166 630 411 0 2 899 618 770 99 1 6 244 832 400 282 8 2 943 106 110 94 1 1 128 57 980 8 2 7 071 829 690 54 2 15 308 17 184 830 4 222 0 4 070 3 4
54. 8 21 JIS 60 gt 8 5 15 19 6 5 50 50 gt 9 10000
55. 30 I lililbi nN 4 EE 2010 12 09 ll
56. 5 10 NEDO 4 000 ig 100 87 44 449 2010 37 A930 e65 2 821 22 2 3 78 64 85 59 118 1
57. NALIC 22 8 O52 744 5110 y 3 0 AS EN EZ RF URL http wwwnalicjp PR 1 2 FR CR R L 5 H 13 1 Ei 2 1 13 7 Me FR VF 2 SP 17 ask jp css com 2 2 Ji es as CLINICAL STUDY SUPPORT ams A 052 784 6321
58. 2 1 15 12 9 ISO13485 17 4 17 4 1 QMS 18 2 14 QMS GVP GQP 2 5 21 gt 2 NIIF roue cpmuev azzsa RIIKOU ICH MEDICAL DEVICES AtANUFACTURERS ASSOckemlOIN AO 3
59. 108 2 a 2005 GCP Good Clinical Practice
60. JA 22 2 23 2 24 15 00 17 30 3 2 48 66 15 00 CLINICAL STUDY SUPPORT
61. CT Produced by CSS 22 22 11 9 22 11 19 14 00 16 50 34 14 0533 67 G611 htto wwwnidekcojp company network plantheadguarters_phtml 13 3O JR
62. dr No 2 2 3 3 2 5 PL 1 PL 2 2 PL 3 3 4 5 6 3 PL PL 2 3 6 4 1 5 2
63. 1 1 o o o 2 o
64. 2005 GCP Good Clinical Practice
65. 300000 R250 000 ni e 200000 150000 3 100000 HR 50000 0 2006 2007 2008 2009 2010 2011 m 1 9 2 3 a 2 500 3 700 340 000 5 800 m 1 500 1 5 5096 50 6096 R amp D
66. 15 1 1 6 9 Produced by CSS 22 100 0 80 0 60 0 40 0 20 0 0 0 2 77 12 6 6 0 4 0 SOS 100 0 80 0 60 0 40 0 21 4 21 4 20 0 3 0 0 3 7 8
67. 22 22 1 1 1 2 1 3 2 1 2 2 3 1 3 2 4 1 2 3 1 2 1 22 1
68. 2 3 16 3
69. TE 10 20 1 0 10 71 OECD 10 2 22 2 22 12 20 14 00 lt 17 00 WINC AICHI 1203 4 4 38
70. 15 12 9 ISO13485 17 4 17 4 1 QMS 18 2 14 QMS GVP GQP 2 5 21 Ge UI 1 2 11 115 4 23 1 107 9
71. 10cm 10cm 2010 12 09 82 5 iBOT3000 2010 12 09 2010 12 09 mmm po
72. 02 0083 3 10 3 3F 03 5212 3721 IM 113 3 39 17 0033 koGA 4F 03 5689 7530 i 4 1 11 0034 5F 03 5805 6131 103 2 2 3 0027 3F 03 6225 5474
73. gt 1000 1980 9500 2 1 30 soma e
74. 31 1 8 19 5 Q1 100 0 80 0 60 0 40 0 20 0 0 0 Produced by CSS 2 2 22 15 17 10 8 2 1 Q2 100 0 80 0 60 0 40 0 2 20 0 a 0 0 DDO
75. 19 3 17 2004 06 30 6 1 1 8 nl eg 4 5 1 1 3 8 2010 6 9 7 4 2007 2008 mm lt F 1 rrWllhii T GVP GPSV GCP DT
76. 4 8 JIS 5 SG Eee 8 4 3 8 JIS 4
77. 2 Poc 8 EE p 2 DM CRS GCP Phase 1 Phase I
78. 3 2 NALIC
79. 34 6 F S P A M 2Z Z PT TORO
80. Produced by CSS 22 6
81. 1 24 NE
82. 4 2 0 3 100 5 0 P R 3 1
83. 7 1 0 2 4 777 32 47 12 5 5 0 2 5 Produced by CSS 22
84. mm etc O O O 80 200g 60 100m 1 200m 1 200 g 7 2
85. HIV 4 3 5 SA 31 6
86. CIC ma SW ez A WW A i Ne 4 8 CIC 8 sis
87. 22 11 12 14 00 16 30 NALIC 2 40 1 CLINICAL STUDY SUPPORT
88. 10000 23 24 2003 101 2038 170 85cm 90cm 9 2005 546 213 2025 738 872 g 47 20 80 RR 9g
89. 1000 1500 i 3 225 000 4 216 000 129 8 J 3130 000 P 9 13 900 000 5 M 0 0 4 e
90. 5 lt IT 6
91. 2
92. o o o 0 QOL RANG NES es A
93. SE PS Falck K et al Lancet 1979 7 10 32 Ames few s ie 7 97 waeeeaeee tiemts valoes e and controls CP CP ng 24hr
94. o o o _ ep a lt 7 ures a 72
95. 107 0052 2 17 62 3 TEL 03 6825 3012 E mail npoikouren doriJjp URL http www dorijp npo index htm FAX 03 5570 0845 m m NPO m NPO 2 7 12 20 f 1
96. 12 3 NN 11 12 14 11 14 70 699 31 575 21 626 30 5 4 176 3 069 2 920 69 9 3 316 1 121 1 079 32 5 12 gt 17 6 100 5 4 93 18 9 19 4 22 8 264 262 306 98 85 121 37 3 32 6 39 6 16 H17 4 17 000 16 500 H17 6 1 8 8 rc a 16866 16 000 15 500 15 000 14 500 14 000 13 500 13 000 12500 in 8 EE S H17 7 10H18 4 7 10H9 4 7 10H20 4 7 10H21 4 7 10H22 4 4 1 1 a
97. 19 22
98. o 3 3 o o o o o o o 7 o o o o o o o o o 1 o o o o o
99. 113 0033 3 22 5 2F 03 5844 3581 113 2 31 24 0034 03 3818 4041 113 8701 3 27 12 03 3817 4231 NPO
100. 460 0002 2 14 4 709 f 052 229 1750 http www aiikou k ord e 10 HP gt P ME EE gt 1 4 SS gt N vy
101. 3 1 2 3 Produced by CSS 22
102. 2 2010 6 18 ET eg 21 hE 2020 7 000
103. 3 rh i tnt i 1
104. Bionetworks i2b2 Translational medicine SmartAmp Harvard 13 22 12 20 NPO 0M NPO a PC NR ad 2 a OS a 9 ur 9 a 4 0952 4 4
105. ON 1 he 6 22 10 1 1 A5 184 2 30 5 PO lo WEB
106. V 3 9 I 1 2 ESg 8 eR EE H18 11 27 Q amp A Q2 Q8 1 HP URL http Www aiikou k org index html 13 00 lt 17 00 1 2 OMS ISO
107. E C60 1 4 N45 5 C70 OI CS CT JR 35 UM 3 C60 CLINICAL STUDY SUPPORT N45 052 784 6321 C70 JR 20 CLINICAL STUDY SUPPORT CSS NICP 22
108. NALIC 2 40 2005 GCP Good Clinical Practice 1 2
109. o o NPO o o o 10 1 o o o o o o o CE o o
110. 32 Produced by CSS 22 17 2 2 0 pe nl 26 19 4 3 0 1 OO 5 3 Produced by CSS 22
111. 13 30 lt 14 00 14 00 14 10 CLINICAL STUDY SUPPORT 14 10 15 00 15 00 16 10 14 22 16 15 16 30 16 40 19 19 7 8 9 15 5 39 4 7 9 3 5 2 7 2 7 9 7 3
112. 14 00 14 10 N y 16 20 16 35 17 00 _ 501 1193 1 1 TEL 058 230 1111 35
113. CLINICAL STUDY SUPPORT O52 784 G321 22 2 22 11 19 14 00 16 40 22 13 30 14 00 14 05 14 30 14 30 15 00 15 00 15 10 15 15 16 10 16 15 16 30 16 30 16 40 16 40 22 3 2
114. 21 14 1 0 0 4 77 Q4 2 8 5 Produced by CSS 22
115. Effect of Metformin on Colorectal Aberrant Crypt Foci K Hosono et al Cancer Prev Res 3 1077 1083 2010 1 Neglected diseases n 1000 5000 I n 100 500 NK h 1DiMasi JA Hansen RW Grabowski HG Journal of Health Economics 2003 22 151 185 10 15 800 2 Global Post Market Regulatory Application Phase IIl n 1000 5000 Phase Il n 100 500 Phase I n 20 100 Preclinical Discovery Research Years Adapted from Pharmaceutical Industry Profile 2007 Washington DC PhRMA March 2007 1DiMasi JA Hansen RW Grabowski HG J Health Economics 2003 22 151 185 1 20 000 9 17 2009 6 92 lt 96 Drug Development Process
116. POC Proof of Concept 2010 4 _PMDA 6 21 _PMDA harescesocals sad Wedeai bevces heeecy http www pmda go jp Harvard Seminar by Dr Tonallato Sep 28 2009 Project Three YCU GC The Oncology group at YCU is joining with Global Cures www clobalcures oro to explore novel approaches to consider previously approved drugs coupled with novel validation studies that include molecular biomarker monitoring to develop evidence for alternative promising therapies IRB CRC GCP
117. 23 6 1 1 0 oO MO NM A Q3 3 2 3 2 Produced by CSS 22 4 77 19 9 2 1 0 OBES QA 3 2 6 5 5
118. JIS C9335 2 211 PSE 2 V QMS JIS T0993 1 B A 0C 0 mm 6
119. o 8 CIC g TIOg 29002 88 2 1
120. H22 12 3 H22 12 15 H23 1 14 H23 1 17 H23 2 2 H23 2 3 H23 2 4 7 22 H23 2 15 H23 2 21 H23 2 7 H23 2 18 H23 2 22 2
121. e e e e e e e 1 amp 3 k a 2 1 2
122. 17 000 300 000 52 20 6 7 2 TR HP T1 Saad Needs T1 Phase T2 Phase Il T3 Phase II Bench to bedside and back The bench to bedside appr
123. 1999 12 120mg 1 3 3 56 11 2 2000 6 5mg 50mg et 2000 10 1 1 hmme Se ne RG50mL 1 ams 2 2002 4 88 8mg Des 2 2003 9 2 9 g 2 2 am 5 8 g 2 5 2003 9 280mg 208 2004 4 TS 1 3 11 Fu250mw 2
124. 120 80 60 40 20 0 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTt 22 30 40 50 60 2 7 19 19 20 OTT TO TT TOT TT 2 HY ee 2 5 2010 12 09 1
125. 1 A063 pc0 0800 im ie os e 8 MSN HH oo o y 6 0 6 0 0 leo to uo Aipsqi 5 un go 1ooo 20 20 24 5 0 2 15 N 1 SD 101 lt lt lt 2 as Rt 3 2 10 ER mv Sp02 1 SD 101 1 6 LIL orn cam DS eIE n 52 ESO BENS era A end DENSO BENGG GONATION A Aha eees 2
126. Produced by CSS 100 0 80 0 60 0 40 0 20 0 0 0 2 36 26 25 12 5 3 NO OU op 100 0 80 0 60 0 40 0 24 3 23 4 20 0 0 0 3 18 35 4 8 0 1 Produced by CSS Q3 12 1 CA 6 1 4 777 18 34 8 4 5
127. 2001 Exacta Mix 2400 EM2400 1990 LIN Riva Intelligent Hospital Systems 5 HE dE yd M CytoCare Health Robotics 1 8 en Rb 2001 2009 19 50 2010 12 09 CFM Mediai Dispensing Systems PharmaHELP _ cetoXC V rormuian9 A Ma chin e _ W
128. Phase 0 Phase 1 POC Global CRO Phase Ma Bioinformatics Systems Biology SAGE Drug Repositioning Harvard Duke rn 2009 9 28 Peter J Tonellato Methodology and Infrastructure for Translational Science Activities in education and research on translational 2009 405 ER VEE research at Tokyo Medical and Dental University Japan 2009 10 19 Vince Fusaro Using Existing Data to Improve Translational Research IClinical and Educational Genomics Personal experiences 09 020 MariBognsk ith direct to consumer genotyping IDisentangling autism through cross disease computational 2009 11 2 Dennis Wall janalysis 2009 11 16 Sandor Szalma ITranSMART data warehouse for translational research irtual Patient Population Convergence A New Framework AShike Konagava for Translational Biomedical Informatics 2009 11 23 Structure of pr
129. FGM 5 NNNN N gt 2 8 6 NN SR bed SN gt PT ADL ADL activiTy of daily living J
130. 69 6 a 20 4 900 T ISO TC210 METIS JFMDA http wwwJfmda grjp 20 3 m HH AM Tn
131. 3 1 1 3 2 2 4 4 22 1 2008 2 1 20 1 090 749 559 160
132. 9 Da N 2 ON QMS 4 ET
133. CE 7 8 kk 1 21 9 SS 19 5 14 30 30 22 3 44 36 22 34 14 19 1 190 20 1 412 21 1 172 3 774 8 8
134. WHO BONE AND JOINT DECADE 2000 2010 2010 12 09 2 2010 12 09 CP J 2010 12 09
135. 22 CLINICAL STUDY SUPPORT 23 3 31 1 22 1 2 1 2 3 Om 1 1 2 2 3 3 4 1 2 5 1 1 2 2 6
136. 19OO 1 0465 81 427O Q http wwwterumocojp company development pranexhtml 13 5O IC O a os cs 71 JR 10 15 1 15 JR 20
137. 5 Om GPS Sr 1 Ph 2010 12 09 30 45 6 1 3
138. NALIC IM http www smrij go p incubation 052 744 5110 nalic index html CLINICAL STUDY SUPPORT CSS NICP 22 3 23 2 1 10 00 12 30 NALIC 2 34 35
139. 2 11 22 12 1 107 9 WO 460 0002 2 14 4 709 052 229 1750 http www ankou k org 2 HP AIGHINIEBDICAL DEVICES MANUFACTURERS ASSOCAIHON a PF SS NE gt AIIKOU 1 2 3 EE 2 HP EE IIKOU WCHI MEDICAL DEVICES MANUFACTURERS ASSOcdAIION RES EZTT Se Se sw cc oles CETTET E 4 3 2
140. 1 2
141. 173 460 2004 GD P 1596 GDP 79 896 GDP 8 2005 2 9 840 65 129 2025 1896 2004 4 5 700 65 179 2025 23 2004 1 2 750 65 2096 2025 3096
142. 14 00 14 10 E 16 20 16 35 17 00 30 98 1 17 50 31 1 Produced by CSS
143. 1 Produced by CSS 22 NPO 100 0 80 0 60 0 40 0 20 0 0 0 2 34 26 17 5 9 6 NPO OO 100 0 80 0 60 0 40 0 20 0 0 0 3
144. 10 2 2 8 3700 30 1 7
145. 3 4 2 4 2 3 1 8 1 1 29 8 89 3 3 1 3 12 22
146. H23 1 11 H23 1 20 H23 1 21 H23 2 2 3 3 3 0 3 3 1 2 1
147. PL E JIRA X X CT MR X uF 2 2 23 0004 2 6F 03 3816 3450 JEITA 44 00 0004 1 1 3 03 5218 1057 ju 0033 3 39 15 5F 03 3816 5575
148. TDM NE 8 ID 00000019 2006 5 10 ID 00000019 63 1 er iy 2006 5 10 2006 5 10 2006 5 11 2006 5 10 65 1 0511 2025 i a 3 2006 5 11 B mi A 25mg 1 100mg 1 1 11 7 A 25mg K5 61 3 5 5 200600501 2E2 100mg 3 A 25mg BUN 60 71 1 40 3 5 11 7 EOE A 25mg Ko 2g s01 3 5710 7 ER gE HAAO HR ABOE
149. ADL 1 2 3 etc ec 24
150. o o 1 425 1 o o 94 o 2 o
151. 3 4
152. Benchto bedside and back The bench to bedside approach is a really two way street NIH Importance of translational medicine Harvard gt CDM Eh ICH GCP CRC ARO Academic Research Organization CDM_ y w CRC CRC CDM
153. 113 2 31 20 8570 9F 03 3818 6047 5 101 1 7 1 0047 5F 03 5283 6244 113 3 39 15 0033 1F 03 3811 6761 JHIDA 101 0047 2 11 1 6F 03 3258 5964 105 0012 2 10 1 7F 03 6403 5351
154. 15 05 JA 17 30 CLINICAL STUDY SUPPORT 17 45 30 53 1 10 24 21
155. 20 8 4 0804001 40 PMDA IDE Investigational Device Exemption PMA Class Il 510 k Class II
156. B B B B A B A A B 0 0 e B Ne A B NA B B A SN NN OA
157. Pa A sR 2 1 2 7 8 1 2 6 IS 0 oD 2 5 2 I 2
158. JIS JIJS 1 21 3 2 22 3 JIS ee 3 0 8 JIS 3 21 7
159. Produced by CSS 22 6 2 1 000
160. 2005 GCP Good Clinical Practice 2 22 12 20 3 23 2
161. e N iA lt ey SQ p 3 Sy er TN ex gt a 8 Nm Ek fy ey rns ye wr SN ww z 22 22 10 22 22 1 1 5 14 OO 16 3O
162. 1 0 13 1 48 100 360 TAIS 02 03 04 05 06 07 08 09 1 5 20 2
163. Te 2 16 14 0056 03 3851 0324 1o1 1 10 1 0054 3F 03 3292 0642 113 5 1 13 0033 ksE 6F 03 5802 5361 1g 3 3 1 0033 KS 4F 03 3811 8522 02 2 2 5 0074 9F 03 5276 9841
164. 1 1 18 1 2 1 2 1 2 1 2 1 2 1 2 1 2 O O oO1O1IOIOIOIOIOIOIOIOIOI 1 2 1
165. 3 1 1 3 O O O 4 EE
166. 16n 2 17n pm PT TI aa own Jl ill NI snus tea mae mens am we 100625 H21 SD 101 6 25 49 2007 9 SD 101 21 4 500 HP GAC GAC
167. H17 4 1 H17 4 1 200 000 750 000 H2 2 6 1 150 000 700000 H1 8 8 1 100 000 ee i 1 1 1 0 523 100 i 18 4 1050 000 600 000 708 300 1 000 000 550 000 H17 12 430 600 950 000 so000 900 000 450 000 0000 PP 400000 800000 Ee H17 7 10H18 4 7 10H19 4 7 10H20 4 7 10H21 4 7 10H22 4 H 2 mt 8 4 1 M y H17 4 2 2 8 121 29 8 171 2 7 1 4 0 7 6 4 0 2 E 1 00 390 000 340 000 25 1 gt 15 3 0 0 RS
168. HP GQP GVP GQP GVP UP I 1 2 2 gt 2
169. 5 09 1 7 3 19 1 4 6 2 4 9 1 9 9 0 8 0 17 22 2 2 3 2 23 2 24 15 00 lt 17 30 3 2 NPO
170. PMDA A SO ea 0 T0993 1 sg 1 2 36 3 gt 2011 23 2 1 e
171. 1 8 3 89 3 59 2 7 1 89 9 3 8 5 6
172. 2010 12 09 ml mm EE lt 5 gt a 6 40cm 2010 12 09 a 2010 12 09 Se
173. PO L M 2 2 2 3
174. da Vinci 6 2000 1995 Intuitive Surgical 2002 2 60 2001 NY ZEUS 976 35 5 1 395 20 ZEUS 2008 J amp J 2009 Siemens Medical Baxter 1 1800 1 1000 Medtronic H Boston Scientific 1 1800 St Jude M e 9 GE Healthcare 1 7800 J amp J mm
175. 2003 2001 Metformin 2008 Merck Rosetta The data is too large for one company to collect 2009 Drs Friend Hartwell SAGE Bionetworks NPO Precompetitive AMPK AMP data Merck SAGE to 2010 NCI SAGE Cancer Systems Biology Center AMPK ATP Directors Stephen H Friend President Co founder ATP Eric E Schadt Co founder an industry leader in network biology AMPK p53 Leland H Hartwell President of Fred Hutchinson Cancer Center 5 p53 Jung Wang Executive Director of BGI Beijing Genomics Institute Metformin LKB1 PAK1 Hans Wigzell Former President of Karolinska Institute etc Metformin
176. Ms a CoO2 6 DENSO DENSO CONPORATON Ah ighs reserved DENSO DENSO CORPORATION All rights reserved 1 1 2 9 47 4 1 1 999 GAC 4 a 2 2 8 3 2 1100 1062 1091 L216 1207 114o BEE 1500 jnoo 500 0 02 03 8 2 3 4 DN SO DENSO CORPORATION Allrights reserved H 6 N 7 N DENSO VISION 2
177. 1 gt HP FAX HP QMS QMS 1 2 HP ESIKGS ABFOU ICH MEDICAL DEVICES MIANUFACTURERS ASSockAION me WR 2 2 e 10
178. 1868 Kussmaul 1932 Shindler 48 50 3 x 60 64 70 2002 PFS Progression Free Survival tN EA 609 hn A453 74 4 497 6 7 PFS 4 PFS PFS 12 PFS Lt OZ41 95 CI 0 6510 845 oo 12 ed
179. 2008
180. 5 9 2 5 9 3 2 2 8 1 99 1 2 3 13 22 9 4 9 7 4 9 9 0
181. 2 3 4 Eeecoxt 1990 Estuzumab ozoqamicrn 1991 1970 1961 FUDR 1982 1992 1962 op DDD 4973 388 5 4953 1963 1974 1987 1994 TEM E C 1964 1975 1988 1954 D 1966 1976 CCNU 9 1967 1959 1977 BSNU 1949 1978 1969
182. F RR OR R 5 HD 13 UR 2 HHD HP 13 http www chubu meti go jp jisedai medical_dev 17 5 ioe indexhtml 2 LE 1 Sse reg oo Se iain a f esnasrers 2 1 14 OO ask jp css com 2 1 se 7 Se 22 8 9 052 784 6321 052 744 5110 CLINICAL STUDY SUPPORT
183. 2 e 30 e 2 e 22 2010 4 24 2012 4 e 1 19 8 ee e 8 22 3 5 0305 7 19 3 i cs a e 35 1 2 1000 2000 127000 e
184. 2007 3106 2008 5842 2009 7270 2007 8066 2008 7569 2009 6547 RA A LRAR RR LR KK e 2007 e 2008 0 2009 2010 15 20mg m 1 1 5 2 25 35mg m 1 1 1 70 90mg m 1 1 3 1 1 100mg m 1 3 4 2 1 1 150mg m 2 2 3 3 1 1 40mg m 3 1 2 3 2 2010 12 09 mFOLFOx5 OlgPS5 Staac 1 T
185. 22 4 30 8 NN 2 3 X 7 6 5 A MN TANMN I dN
186. 17000 11600 15800 oh 6500 UK2 9600 40000 4600 7000 10 290 000 240 000 190 000 i 1 i n 140 000 90 000 PS 2 2 9 2 2 6 7218 897 7370 393 gt 1 070 644 1 975 468 gt 7031 374 161 719 806 751 gt 1 232 782 gt 7362 392 1 232 363 2 782 219 a 7 0 00 54 4 2 5 2 50 0 7 1 22 8
187. gt 8 135 200 1 026 600 2 413 000 i 75 400 1 105 300 135 200 92 400 910 100 822 100 845 900 Information Explosion Serendipity by Design 1 Life Science Data Explosion Systems Biology amp Bioinformatics Metabolomics prorsomics EE Variations_ Sequence Data Records Literature 9 Integration of Data for Breaking the Understanding of causal relationship between genomic variations PB threshold 2008 and genetic mutations with diseases Breaking t
188. 22 5 Produced by CSS 22 100 0 80 0 60 0 40 0 20 0 0 0 2 77 19 16 11 9 6 1 BE 100 0 80 0 60 0 40 0 0 17 7 14 5 20 0 0 0 3 25 11 0 0 0 Wo ol Produced by CSS 22
189. 6 4 2 2 2 22 11 19 14 00 16 40 13 30 lt 14 00 14 00 14 05 14 05 14 30 14 30 lt 15 00 3 15 00 lt 15 10 15 15 lt 16 10 2 16 15 16 30 16 30 16 40 15
190. 3 2 SS gt rm ISO13485 QMS 1 gt 1 A
191. 60 363 1 76 24 58 608 412 ns 22 3 1 1 A B C A B C 9 PFS Progression Free Survival EGFR PFS EGFR EGFR a 9 na 132 9Z73 3 91 58 96 7 129
192. CDM Ranking of basic and clinical research IMD International Institute for Basic Research Clinical Research Management Development Nature Medicine Cell J Exp Med New Engl J Med Lancet JAMA 1993 97 1998 2002 2003 07 1993 97 1998 2002 2003 07 USA 3 097 2769 1 2674 1 3314 1 3695 1 2677 1 y Ss 1 Germany 321 3 404 2 442 2 253 6 511 3 343 4 8 Japan 236 6 371 3 369 3 122 12 183 12 74 18 3 15 UK 365 2 352 4 314 4 920 2 1484 2 873 2 France 239 5 256 5 269 5 274 5 432 5 300 5 Canada 227 7 209 6 204 6 377 3 502 4 462 3 China 1 36 8 25 53 13 20 30 59 21 102 15 Korea 15 22 39 18 IMD 2009 q IMD 1 3 5 2o 1 6 3 6 8 DE KR Da I
193. 35 145 14 1 14 9 5 PMDA gt 1 Ww 8 gt 1 0 2 rd
194. H HH lt J QOL 23 2 24 15 00 17 30 3 2 1 000 160 2008
195. HP http www med nagoya Ua HP http www chubu meti gojp jisedai medical_device index html 1 cjp medical 1919 2342 O 5 html 052 784 6321 ask jp css com 2 24 CLINICAL STUDY SUPPORT CNICAL STUDY SUPPORT CSS NICP 22
196. Q amp A Q amp A e NN 1 1 w 1 11 91
197. 22 1 11 12 100 0 80 0 60 0 40 0 20 0 0 0 2 74 31 38 5 8 5 IT 100 0 80 0 60 0 0 40 0 Jo 1g23 5 20 0 3 1 4 9 3 1 0 0 3 44 Produced by CSS 22
198. EE 2 22 3 1 9 1 19 2 20 3 20 4 20 4 2 1 1 2 1 2 21 3 2 1 4 2 1 5 2 1 3 22 1 1 1 1 2 2 1 3 3 2 1 2 2
199. 1 2 3 4 5 6 500 7 600 12 700 15 500 19 000 23 000 15 300 1 2 4 5 3 1 H21 3 H21 10 7113 7081 1892 1884 9616 9512 1452 1419 6595 6576 3028 2962 2912 2879 6278 6273 2975 2970 1140 1136 7990 7555 15070 15272 3
200. 2 3 2 1 10 00 lt 12 30 3 armocdAwr iE 34 35 8 8 6 3 1
201. 22 12 9 ne a 1 2 3 4 EE 1 mm a 2010 12 09 CFP___ a 2 ls 3 2010 12 09 430 530mm mmm 5 500m m m
202. 5 2 3 1 2 3 4 96 QMS
203. Bc ee N e kp
204. Fa 2 WSO WSO DENSO CORPORATION Al rights reserved DENSO CORPORATION Al rights reserved 2 2 m SAs SAS Sleep Apnes Syndrome SAS SAS SAS JR
205. Quality Of Life QOL JA 48 66 18 22 8 0 3 5 3 4 49
206. 1 8 780 2 2 3 680 K601 1 1 24 500 2 2 5 3 000 1 a lt 000 3 K602 1 Hi 1 11 100 2 2 3 120 2 2 e SN s 1 Hm As
207. 1 Li SAS AHI20 Me 4 Chest 1908 x DENSO a DENSO a 2 om 2 11in SD 101 gt 9 40 gt 3 0 gt eto 200 2 000 EE gt PSG 2 21900BZX00431000 DENSO DENSO DENSO CORPORATION AI righ
208. 21CFR Part812 ISO 10993 2003 JIS T 0993 1 2005 ECr7 PCD 4J pm Ar 1 Rar Ee 2003 No 36 PMDA 0331 7 2 3 31 La
209. 5 1 3 8 1 a hd 4 1 EE PTCA CABG sae 9 1 2 5 IRB IRB 97 GCP 08 GCP IRB
210. DENSO CORPORATION Al rights reserved DENSO DENSO DENSO CORPORATION Allrights reserved 2 18 2007 11 30 Correlation between AHIl on PSG and RDI on SD 101 eventsJhour of recording time ns201 2 19 N 07 6 10 10 DENSO DENSO 3 DENSO DENSO 3 22 3 23 2 1 10 00 12 30
211. 0 0 0 Wo ol Produced by CSS 22 4 3 12 0 0 0 77 OOON Q4 5
212. 16 22 22 12 9 14 00 lt 16 45 92 122 8 0 3 9 8
213. Intellifill i v For Hearth Technologies 3 5 1 4 2010 12 09 1 2 1
214. 35 5 a PT OT PTOT PT OT 19 7 10 6 KA
215. Broad patient population Responders only 10 12 57 gt 1 lt 500 5 10 25 50 gt 2 000 gt 600 Source Pharma 2010 The Threshold of Innovation 65 1960 1970 1980 1990 2000 2005 2010 2020 2030 2040 2050 0 75 nt tonite pee A re tram oo or a te OCD ea i 2005 2020 2035 33 56 62 85 92 1995 2006 2025 15 64 a PTCD 8 425 6 992 SE i 65 2 085 2 720 PTCA 340 520
216. NCP 1 _ 1 e 7 7 e 17 4 NE XE FT 17 4 gt gt
217. 1 1 1 22 11 12 14 00 16 30 1 CSS 10 22 45 4 8 7 5 0 3 6 5 69 3 1 9
218. a a HP http www chubu meti g0 jp jisedai medical_device index html 1 ask jp css com 450 0002 4 4 38 Peek MIN MA TEL 052 571 6131 9 00 20 00 8 2 URL http www winc aichijp CLINICAL STUDY SUPPORT CSS NICP 2 22 12 20 14 00 17 00 WINC AICHI 1203 71 84
219. ng 24hr 64 9 20 3 HEPA 2010 12 09 Sherry G et al N Eng J Med 1985 Odds Ratio 95 3 96 1 31 to 11 97 2 66 1 25 to 5 71 5 Fu 1 70 0 55 to 5 21 2 46 1 31 to 11 97 0 10 1 00 10 00 C CP MM 7 C 2 7 6 C 51 4 W 128 6 8 232 1 11 1 9 3 225 1 6 8 NN 20
220. scientific integrity clinical care for unmet medical needs public health Entgalyu yisX 7709 HBD Japan USA Program 12 10 10 gt OHRP FWA CDISC CDASH Alphadas Faculty NTT PMDA KA Bionetwo edicine 24 EI 10500Fio se wentes to CT GCOE HBD GCOE FDA Duke
221. 1 2 7 X 2 6 MRI 3 ISO13485 QMS Ng 2 2
222. 111 86 0 85 70 82 4 0 48 2 85 5 Cl 2 05 3 98 9 00O1 9 LE 132 IO6 271 3 3 0 9 21 129 103 3Z 2 s5 55 ma Trootment by swbgroup interoction al p lt 0 0001 Cox V15 32 Gefitinib Docetaxel 245 244 156 Probability 1 00 poo of survival HR 35 2496 CH 1 12 0 89 140 p 0 330 Median months 11 5 1 year suvival 48 Supportive Cox analySiS With covariates HR 95 CI 1 01 0 80 1 27 p 0 814 Pa 273 2000 2002 2004 2006 2008 2009 2008 3 867 647 5 2009 1395 1395 867 528 528 195 333 Ac
223. 1979 Ara C 1960 1970 1980 1990 2000 2010 2007 2008 2009 RR RR Re 2007 2008 2009 0 RRAR RR RR RA RK A 2007 2008 O 2009 2010 1 2 3 4 2010 12 09
224. 22 16 40 22 22 6 8 2 15 5 69 3 8 4 3 2 1 2 19 8 5
225. 7 3 5 0 0 Wo ol Produced by CSS 22 4 4 5 6 0 0 77 5 30
226. CLINICAL STUDY SUPPORT CSS NICP 22 1 22 11 12 14 00 16 30 NALIC 2 45 48 CLINICAL STUDY SUPPORT 36 1 12
227. DR tt 3 EU 38 1 0 500 1 000 1 500 2 000 2 500 0 1000 2000 Oct 16 2007 Clinical development cost per patient in Japan is more expensive than that in US Clinical development cost per patient in Japan is 1 6 3 3 times more expensive than that in US 1 6 4 4 times Clinical Development Cost Per Patient Source Fast Track R amp D Head Club Report 2004 87 6O 413 5 i 2 2008 gt ET 1 02wssWs04 06 00 02mmmwWe04 CRA 2 gt 4
228. 1 1 DO 5 Produced by CSS 3
229. 1600BZZ00466000 1 1 A _ yy e e e e
230. 3 re EN sgx 2 2010 12 09 Ee tis 1 2 3 4 2006 122816 x INTF a a gt gt Sm TT
231. 3 1 9 2 6 1 8 9 7 2 2 1 2 22 12 20 14 00 lt 17 O00 WINC AICHI 1203 2
232. 400me n2 EiB2 463 Reich S D et al 1975 Doll D C 1989 Rosner F 1976 Ce McLendon B F et al 1978 Ladik C F et al 1980 Crudi C B et al 1982 Gundersen S 1976 WHO IARC Group1 Group2A Group2B Carcino
233. NW IRB C IRB 2 NW NW NW C IRB IT System IT GCP 1 Nw 2030 IT 10 3 NW CRC IRB IRB NW GCP
234. R A IN TR EEO SSA 1 160 Sem 43kg 31 y 060501 K 6 Dr 2006 2 28 2007 4 EE ms a EE 2010 12 09 2 1 2 3 4 TPN 1991
235. a O FE EY E lt Z w
236. and successful model for personalized medicine Overdosing may cause bleeding and insuffcient dosing may create blood clot and hromboembpolic events Even if CYP2C9 and VKORC1 genotypes as well as age gender weight race amiodaron use smoking DVT are taking Into account for defining the warfarin dose the Duke DCRI ARO 20 12 20 Current Activities amp Future Vision of DCRI Global Collaborations Such as HBD Mitchell W Krucoff MD FACC Professor of Medicine Cardiology Duke University Medical Center Director Duke Clinical Research Institute DCRI Functional Operations Customized One Stop Shopping Services Scientific and Project Clinical Hotline Leadership Site Management and Biostatistics Monitoring Data Management EDC Clinical Events Review Site Contracts and Payments Regul i Safety Surveillance egulatory Services IVRS eECG Core Laboratory Medical Communications Practice Guidelines amp Technology Adoption Imaging Core Laboratories Duke Clinical Research Institute gt 1 000 faculty amp staff 205 faculty gt 100 M annual activity 2 3 gt 130 M annual activity i world s largest ARO Th et rechoice not for profit Academic faculty interest driven mission academic amp
237. genic to human Probably Carcinogenic to human Possibly Carcinogenic to human S 3 ES DDT EE 12
238. gt MSc in Medical Statistics CLINICAL STUDY SUPPORT CRC CLINICAL STUDY SUPPORT CRC 9 6 22 MBA
239. he Identifying new molecular targets TB threshold Pharmacogenetic patient subpopulation 2004 100GB Personalized medicine 2002 To predict clinical outcome 10GB ga 2000 To select the personal best therapy 1990 Drug Repositioning www horison com 2004 08 newrules_pg34 eene Expression Methylation Imaging 1450 1870 ww Ll il A ul wm 3500 DARPA Molecular Biology Revolution 1993 World Wide Web Genomic amp Genetic Revolution 1970 SAGE Bionetworks Serendipity by Design 2 Metformin Drug Repositioning 1995 Dr L Hartwell recruited Dr S Friend at Fred Hutchinson Cancer 1922 _E W J Belland Metformin Research Center for an advanced drug discovery erner Belland Metformin 1996 L Hartwell L Hood S Friend Rosetta DNA microarray 1927 1957 Stern 2001 Merck Rosetta Stephen Friend Merck Sr VP 1958 UK Dr Leland Hartwell 1961
240. oach is a really two way street NIH Importance of translational medicine Harvard 8S gt 40 20 4096 TR HP g TR se ll PA ge ll
241. otein interaction network and their implication Hiroshi Tanaka on drug design Status of translational and clinical research in Japan and 2009 11 30 Yutaka Natsumeda SE CU s vision 2009 1277 Vikas P SukhatmePromoting Translational Medicine Vince Fusaro 2009 12714 losing Remarks on the Fall 09 Palaver Peter J Tonellato Harmonisation PMDA ICH HBD Joint graduate course Bridge Japanese data to i2b2 TTWech Scientific and cultural exchanges Compare genomic and environmental factors RIKEN Joint oncology trials VA Develop bilingual physicians and staffs Flal Cues YNU Share infrastructure to support clinical trials Beth Israel Deaconess Medical Center Department of Pathology a sei d Tuesday March 2 from 2 4 pm in Countway 403 The BIDMC Department of Pathology he Laboratory for Personalized Medicine and the Wall Lab are pieased to host two presentations on transilational medicine from researchers at Yokohama Ciy University Please join us to learn more about the excitng translational medicine programs at Yokohama City University Importance of International Interactions and Barriers between Biology and the Bedside Yutaka Natsumeda M D Ph D Professor of Clinical Research Yokohama City University Graduate School of Medicine Pharmacogenetic and bioinformatic approach to predict warfarin clinical dose is regarded as a useful
242. ts reserved DENSO CORPORATION All rights reserved 2 SD 101 1235mm 162 02 a 2 13 n Fa es ET 3 Ww Cm G me 2F 5 r 0 919 0 EE 0 1 2 3 4 5 6 42 9 794 802 2004 DENSO J CO ME FE DENSO DENSO CORPORATION All rights reserved 2 SD 101 PSG AHI CPAP

Download Pdf Manuals

image

Related Search

Related Contents

  HTX-55/77HDX  Philips AZ3811  User_manual_for_SG562-BW_20150422_V1.0  Notice d`instruction  

Copyright © All rights reserved.
Failed to retrieve file